Status | Study |
Completed |
Study Name: Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR Condition: Nephrogenic Systemic Fibrosis Date: 2010-06-01 Interventions: Drug: Ablavar One dose of Ablavar will be administered for use during a contrast MRI examination |
Terminated |
Study Name: Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF) Condition: Nephrogenic Fibrosing Dermopathy Nephroge Date: 2010-02-05 Interventions: Procedure: Plasmapheresis A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to |
Completed |
Study Name: Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels Condition: Nephrogenic Systemic Fibrosis Nephrogenic Date: 2009-11-13 |
Suspended |
Study Name: Nephrogenic Systemic Fibrosis With Gadollinum Condition: Nephrogenic Systemic Fibrosis Renal Failure Date: 2009-10-26 Interventions: Drug: gadollinum use of on injection gadollinum Iv for imaging |
Completed |
Study Name: Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec Condition: Nephrogenic Systemic Fibrosis Date: 2009-09-21 Interventions: Drug: Imatinib mesylate (Glivec) 400 mg, one tablet daily for 12 or 24 weeks |
Completed |
Study Name: Primovist / Eovist in Renally Impaired Patients Condition: Contrast Media Date: 2009-05-26 Interventions: Drug: Gadoxetic acid disodium (Primovist, BAY86-4873) Primovist/Eovist in approved indications at approv |
Completed |
Study Name: Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI) Condition: Chronic Kidney Disease Renal Insufficiency Date: 2009-05-13 Interventions: Drug: Omniscan OMNISCAN will be administered intravenously at the medical discretion of the prescribing |
Completed |
Study Name: Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis Condition: Nephrogenic Systemic Fibrosis Date: 2009-03-17 |
Suspended |
Study Name: Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection Condition: Nephrogenic Systemic Fibrosis Renal Insufficiency Date: 2008-12-18 |
Completed |
Study Name: Safety of Gadovist in Renally Impaired Patients Condition: Fibrosis Renal Impairment Date: 2008-12-18 Interventions: Drug: Gadobutrol (Gadovist, BAY86-4875) Gadovist in approved indications at approved dosages |